P. Larsson

Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes

P. Karlsson, K. Helou, Hanna Engqvist, 2020, Scientific Reports.

Pan-cancer analysis of genomic and transcriptomic data reveals the prognostic relevance of human proteasome genes in different cancer types

Toshima Z. Parris, Eva Forssell-Aronsson, P. Karlsson, 2022, BMC Cancer.

Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes

Toshima Z. Parris, P. Karlsson, K. Helou, 2020, Scientific Reports.

Pan-cancer analysis identifies BIRC5 as a prognostic biomarker

Toshima Z. Parris, K. Helou, Z. Einbeigi, 2022, BMC cancer.

Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens

Eva Forssell-Aronsson, Per Karlsson, Toshima Z. Parris, 2020, Scientific Reports.

Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens

Eva Forssell-Aronsson, P. Karlsson, K. Helou, 2020, Scientific Reports.

Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in vitro

Toshima Z. Parris, P. Larsson, Maxim Olsson, 2023, Frontiers in cell and developmental biology.

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy

Xiao-Feng Sun, P. Larsson, Jing Zhang, 2023, Molecular cancer therapeutics.

Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Toshima Z. Parris, A. Abramsson, K. Helou, 2024, Cell death discovery.